MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 09-10-2025
Anixa Biosciences Cost of Revenue 2011-2026 | ANIX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Quarterly Cost of Revenue Anixa Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 595 K | - | - | 2.84 M | 1.09 M | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.84 M | 595 K | 1.51 M |
Cost of Revenue of other stocks in the Diagnostics research industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
162 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
608 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
6.6 M | $ 22.03 | 3.19 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
9.45 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
144 M | $ 22.9 | 19.89 % | $ 246 M |  China |
 |
Biocept
BIOC
|
28.4 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
38.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
30.4 M | $ 1.6 | -0.62 % | $ 2.03 M | USA |
 |
Co-Diagnostics
CODX
|
4.18 M | $ 6.05 | 6.14 % | $ 178 M | USA |
 |
Castle Biosciences
CSTL
|
60.2 M | $ 40.8 | 1.83 % | $ 1.13 B | USA |
 |
DermTech
DMTK
|
15 M | - | -11.32 % | $ 2.94 M | USA |
 |
Danaher Corporation
DHR
|
9.67 B | $ 234.89 | -0.73 % | $ 172 B | USA |
 |
DarioHealth Corp.
DRIO
|
14.4 M | $ 12.11 | -10.18 % | $ 344 M | Israel |
 |
Global Cord Blood Corporation
CO
|
183 M | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
1.33 B | $ 70.15 | 0.37 % | $ 27.1 B | USA |
 |
Genetic Technologies Limited
GENE
|
276 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
194 M | - | 0.12 % | $ 80.1 M | China |
 |
Enzo Biochem
ENZ
|
17.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
221 M | $ 101.62 | -0.03 % | $ 18.8 B | USA |
 |
CareDx, Inc
CDNA
|
45.5 M | $ 18.99 | 0.96 % | $ 1.02 B | USA |
 |
Fulgent Genetics
FLGT
|
176 M | $ 27.97 | 7.62 % | $ 846 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
9.99 B | $ 29.05 | 1.22 % | $ 20 B |  Niderland |
 |
Aspira Women's Health
AWH
|
3.86 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
146 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.57 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
10 B | $ 244.09 | 1.5 % | $ 44.3 B | USA |
 |
Illumina
ILMN
|
1.51 B | $ 151.07 | 2.65 % | $ 24 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
6.63 B | $ 178.22 | -1.22 % | $ 19.8 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.38 B | $ 253.83 | -2.49 % | $ 21.3 B | USA |
 |
Motus GI Holdings
MOTS
|
81 K | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
3.97 B | $ 202.64 | 0.58 % | $ 16.7 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.52 B | $ 710.27 | 0.49 % | $ 58.6 B | USA |
 |
Lantheus Holdings
LNTH
|
546 M | $ 69.22 | -0.66 % | $ 4.79 B | USA |
 |
Agilent Technologies
A
|
2.91 B | $ 147.47 | -0.1 % | $ 44.8 B | USA |
 |
Biomerica
BMRA
|
4.81 M | $ 2.78 | 5.41 % | $ 6.39 M | USA |
 |
Bioventus
BVS
|
184 M | $ 7.56 | -1.18 % | $ 474 M | USA |
 |
QIAGEN N.V.
QGEN
|
801 M | $ 47.23 | 0.32 % | $ 10.5 B | Niderland |
 |
Myriad Genetics
MYGN
|
252 M | $ 6.7 | 2.68 % | $ 607 M | USA |
 |
ENDRA Life Sciences
NDRA
|
173 K | $ 4.51 | -1.96 % | $ 2.42 M | USA |
 |
NeoGenomics
NEO
|
370 M | $ 12.69 | -0.78 % | $ 1.61 B | USA |